Free Trial

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

+0.03 (+1.09%)
(As of 07/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
15,397 shs
Average Volume
75,877 shs
Market Capitalization
$59.86 million
P/E Ratio
Dividend Yield
Price Target

Aileron Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Strong Buy
3.50 Rating Score
585.9% Upside
$19.00 Price Target
Short Interest
1.43% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$248,685 Sold Last Quarter
Proj. Earnings Growth
From ($1.36) to ($1.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

478th out of 894 stocks

Pharmaceutical Preparations Industry

225th out of 426 stocks

ALRN stock logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

ALRN Stock Price History

ALRN Stock News Headlines

270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
ALRN Aileron Therapeutics, Inc.
See More Headlines
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Strong Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.41 per share


Free Float
Market Cap
$59.86 million
Not Optionable
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

ALRN Stock Analysis - Frequently Asked Questions

How have ALRN shares performed this year?

Aileron Therapeutics' stock was trading at $3.05 at the beginning of 2024. Since then, ALRN shares have decreased by 9.2% and is now trading at $2.77.
View the best growth stocks for 2024 here

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its quarterly earnings results on Monday, May, 20th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.72.

When did Aileron Therapeutics' stock split?

Shares of Aileron Therapeutics reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Aileron Therapeutics IPO?

Aileron Therapeutics (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK) and Amarin (AMRN).

This page (NASDAQ:ALRN) was last updated on 7/23/2024 by Staff

From Our Partners